BRAF Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma1
NRAS Mutation OR KRAS Mutation OR BRAF Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID11061 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
Diffuse Large B-Cell Lymphoma1
BRAF Mutation	(oncogenic)	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11937 This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including BRAF. PMID 22343534 · Lohr et al., 2012 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Colorectal Adenocarcinoma1

NRAS Mutation OR KRAS Mutation OR BRAF Mutation

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID11061

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

civic

Diffuse Large B-Cell Lymphoma1

BRAF Mutation

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11937

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including BRAF.

PMID 22343534 · Lohr et al., 2012 ·

Malignant Colorectal Neoplasm12
BRAF Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID6302 This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID6307 This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID7158 In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
BRAF Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID7159 A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients)… (full text at CIViC) PMID 24112392 · Clancy et al., 2013 · Open in CIViC	civic
BRAF Mutation	Bevacizumab	Predictive	B	Supports Resistance	3	accepted	EID6305 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	Cetuximab	Predictive	B	Supports Resistance	3	accepted	EID6306 This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	Cetuximab	Predictive	D	Supports Resistance	2	accepted	EID1704 A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC) PMID 22586653 · Bertotti et al., 2011 · Open in CIViC	civic
BRAF Mutation	Cetuximab + ChemotherapyCombination	Predictive	B	Supports Resistance	3	accepted	EID2187 This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were K… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
BRAF Mutation	Cetuximab + PanitumumabSubstitutes	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1404 A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targ… (full text at CIViC) PMID 25673558 · Pietrantonio et al., 2015 · Open in CIViC	civic
BRAF Mutation	Irinotecan	Predictive	B	Supports Resistance	3	accepted	EID6304 This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	Oxaliplatin	Predictive	B	Supports Resistance	3	accepted	EID6303 This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Mutation	Regorafenib	Predictive	C	Supports Resistance	2	submitted	EID13264 In a retrospective cohort of patients with refractory metastatic colorectal cancer treated with regorafenib, the four patients whose tumors harbored BRAF mutations all had progressive disease and expe… (full text at CIViC) PMID 33224274 · Lee et al., 2020 · Open in CIViC	civic

Malignant Colorectal Neoplasm12

BRAF Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID6302

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID6307

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID7158

In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

civic

BRAF Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID7159

A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients)… (full text at CIViC)

PMID 24112392 · Clancy et al., 2013 · Open in CIViC

civic

BRAF Mutation

Bevacizumab

Predictive

Supports Resistance

accepted

EID6305

This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

Cetuximab

Predictive

Supports Resistance

accepted

EID6306

This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

Cetuximab

Predictive

Supports Resistance

accepted

EID1704

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

civic

BRAF Mutation

Cetuximab + ChemotherapyCombination

Predictive

Supports Resistance

accepted

EID2187

This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were K… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

BRAF Mutation

Cetuximab + PanitumumabSubstitutes

Predictive

Does Not Support Sensitivity Response

accepted

EID1404

A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targ… (full text at CIViC)

PMID 25673558 · Pietrantonio et al., 2015 · Open in CIViC

civic

BRAF Mutation

Irinotecan

Predictive

Supports Resistance

accepted

EID6304

This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

Oxaliplatin

Predictive

Supports Resistance

accepted

EID6303

This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

BRAF Mutation

Regorafenib

Predictive

Supports Resistance

submitted

EID13264

In a retrospective cohort of patients with refractory metastatic colorectal cancer treated with regorafenib, the four patients whose tumors harbored BRAF mutations all had progressive disease and expe… (full text at CIViC)

PMID 33224274 · Lee et al., 2020 · Open in CIViC

civic

Malignant Neoplasm1
BRAF Mutation	Trametinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID936 In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A… (full text at CIViC) PMID 22169769 · Jing et al., 2012 · Open in CIViC	civic

Malignant Neoplasm1

BRAF Mutation

Trametinib

Predictive

Supports Sensitivity Response

accepted

EID936

In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A… (full text at CIViC)

PMID 22169769 · Jing et al., 2012 · Open in CIViC

civic

Multinodular and Vacuolated Neuronal Tumor1
BRAF Mutation OR FGFR2::v Fusion OR MAP2K1 Mutation	(diagnostic)	Diagnostic	C	Supports Positive	3	submitted	EID12458 Eight MVNT cases (6 pure MVNT and 2 with ganglioglioma-like features) were examined, comprising 4 males and 4 females aged 11–63 years (median 39). Tumors were localized to the temporal lobe (n=7) or … (full text at CIViC) PMID 29428973 · Pekmezci et al., 2018 · Open in CIViC	civic

Multinodular and Vacuolated Neuronal Tumor1

BRAF Mutation OR FGFR2::v Fusion OR MAP2K1 Mutation

(diagnostic)

Diagnostic

Supports Positive

submitted

EID12458

Eight MVNT cases (6 pure MVNT and 2 with ganglioglioma-like features) were examined, comprising 4 males and 4 females aged 11–63 years (median 39). Tumors were localized to the temporal lobe (n=7) or … (full text at CIViC)

PMID 29428973 · Pekmezci et al., 2018 · Open in CIViC

civic

Pilocytic Astrocytoma1
BRAF Mutation OR v::BRAF Fusion	(diagnostic)	Diagnostic	C	Supports Positive	3	submitted	EID7149 Genetic alterations in 96 patients with pilocytic astrocytoma (PA) were evaluated. In addition to KIAA1549-BRAF fusions, other BRAF mutations and fusions were identified. Known MAPK activating events… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC	civic

Pilocytic Astrocytoma1

BRAF Mutation OR v::BRAF Fusion

(diagnostic)

Diagnostic

Supports Positive

submitted

EID7149

Genetic alterations in 96 patients with pilocytic astrocytoma (PA) were evaluated. In addition to KIAA1549-BRAF fusions, other BRAF mutations and fusions were identified. Known MAPK activating events… (full text at CIViC)

PMID 23817572 · Jones et al., 2013 · Open in CIViC

civic

Solid Neoplasm1
NRAS Mutation OR KRAS Mutation OR BRAF Mutation	Lifirafenib	Predictive	B	Supports Sensitivity Response	2	submitted	EID12641 In a first in human open label phase 1 dose escalation and expansion study of lifirafenib in advanced solid tumors (NCT02610361; n = 131; BRAF-mutated n = 53, KRAS/NRAS-mutated n = 66; biomarker BRAF … (full text at CIViC) PMID 32182156 · Desai et al., 2020 · Open in CIViC	civic

Solid Neoplasm1

NRAS Mutation OR KRAS Mutation OR BRAF Mutation

Lifirafenib

Predictive

Supports Sensitivity Response

submitted

EID12641

In a first in human open label phase 1 dose escalation and expansion study of lifirafenib in advanced solid tumors (NCT02610361; n = 131; BRAF-mutated n = 53, KRAS/NRAS-mutated n = 66; biomarker BRAF … (full text at CIViC)

PMID 32182156 · Desai et al., 2020 · Open in CIViC

civic

Low-grade Serous Ovarian Carcinoma1unmapped disease
BRAF Mutation	Trametinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID13127 GOG-281/LOGS was a multinational, open-label, randomised phase 2/3 study evaluating trametinib against conventional therapy in recurrent low-grade serous ovarian or peritoneal carcinoma. A total of 26… (full text at CIViC) PMID 35123694 · Gershenson et al., 2022 · Open in CIViC	civic

Low-grade Serous Ovarian Carcinoma1unmapped disease

BRAF Mutation

Trametinib

Predictive

Supports Sensitivity Response

submitted

EID13127

GOG-281/LOGS was a multinational, open-label, randomised phase 2/3 study evaluating trametinib against conventional therapy in recurrent low-grade serous ovarian or peritoneal carcinoma. A total of 26… (full text at CIViC)

PMID 35123694 · Gershenson et al., 2022 · Open in CIViC

civic

Evidence by cancer (19 items)

Clinical significance (0)